A Single-center, Open-label, Randomized, Two-way Crossover Phase 1 Study to Compare the Single-dose Pharmacokinetics of Different Tablet Formulations of Aprocitentan in Healthy Subjects
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Aprocitentan (Primary)
- Indications Hypertension; Resistant hypertension
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 07 Apr 2022 Status changed from recruiting to completed.
- 25 Jan 2022 New trial record